A recent study found that up to 40% of cases initially diagnosed as high-grade endometrial endometrioid adenocarcinomas may be reclassified as uterine serous carcinomas based on a panel of four immunostains (p53, p16, estrogen receptor (ER), and mammaglobin) [10]. This evidence concerns the gene ESR1 and endometrial serous adenocarcinoma.